Market Overview

Bristol-Myers Squibb Enters 3-Year Agreement with Reckitt Benckiser Group for Over-the-Counter Medicines

Related BMY
Galectin Therapeutics Reports First Patient Dosed in Cohort 1 of Phase 1B Clincial Trial of GR-MD-02 in Combo with Ipilimumab in Metastatic Melanoma
Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions As A Backdrop
Drug Giants Advance Cancer Treatments (Fox Business)

Bristol-Myers
Squibb Company (NYSE: BMY) today announced it has entered into a
three-year collaboration agreement with Reckitt Benckiser Group plc
(OTC: RBGLY) for several of its over-the-counter medicines currently sold
across Latin America, primarily in Mexico and Brazil.

Under the terms of the collaboration agreement, Reckitt Benckiser will
pay Bristol-Myers Squibb an upfront payment in the amount of $438
million for the exclusive rights to sell, distribute and market the
following medicines for a three-year period: Picot, an antacid, Tempra,
a pain reliever and fever reducer, Micostatin, an antifungal, and
Graneodin, a cough and cold medicine, sold primarily in Mexico; and
Dermodex, an anti-rash cream, Luftal, an anti-gas medicine, and

See full press release

Posted-In: News Guidance Contracts Management

 

Most Popular

Related Articles (BMY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free